The Safety and Efficacy of the Repeated PRRT with [
Journal
International journal of endocrinology
ISSN: 1687-8337
Titre abrégé: Int J Endocrinol
Pays: Egypt
ID NLM: 101516376
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
12
2020
accepted:
13
01
2021
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
9
2
2021
Statut:
epublish
Résumé
The peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours (NETs). The study aims to evaluate the safety, efficacy, and progression-free survival (PFS) of patients after retreatment (R-PRRT) and re-retreatment (RR-PRRT) with tandem isotopes [ The median follow-up was 88 months (the range: 42-164). The median cumulative administered activity was 22.2 GBq (the range: 17.8-30.7 GBq). Myelodysplastic syndrome occurred in one patient (3.8%), and grade 4 renal toxicity was also detected in one patient (3.8%). No other cases of grade 3 or 4 bone marrow and renal toxicity were observed. The median PFS rate was 31 months after the PRRT and 23 months following the R-PRRT. The OS rate from the diagnosis (OS-d) was 109 months and from the start of the PRRT (OS-t)-92.4 months. During the restaging, 3-6 months after the PRRT, PR, SD, and PD were observed in 19.2%, 80.8%, and 0% of the patients, respectively. After the R-PRRT, PR, SD, and PD were observed in 50%, 42.3%, and 7.7% of the patients, respectively. The repeated therapy with [
Identifiants
pubmed: 33552155
doi: 10.1155/2021/6615511
pmc: PMC7847334
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6615511Informations de copyright
Copyright © 2021 Anna Zemczak et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest regarding this article.
Références
Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):205-10
pubmed: 24030668
Nucl Med Commun. 2018 Mar;39(3):236-246
pubmed: 29315138
J Nucl Med. 2005 Jan;46 Suppl 1:62S-6S
pubmed: 15653653
Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1788-97
pubmed: 21553086
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):922-933
pubmed: 31980909
BMC Cancer. 2019 Aug 8;19(1):788
pubmed: 31395036
J Endocrinol Invest. 2009 Apr;32(4):360-9
pubmed: 19636207
Endokrynol Pol. 2020;71(3):240-248
pubmed: 32293704
J Nucl Med. 2007 Jan;48(1):134-42
pubmed: 17204710
Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73
pubmed: 19995807
J Clin Oncol. 2011 Jun 10;29(17):2416-23
pubmed: 21555692
Br J Radiol. 2018 Nov;91(1091):20180041
pubmed: 29513039
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35
pubmed: 21892623
Q J Nucl Med Mol Imaging. 2010 Feb;54(1):92-9
pubmed: 20168291
Semin Nucl Med. 2002 Apr;32(2):123-32
pubmed: 11965607
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):5-19
pubmed: 25273832
J Nucl Med. 2017 Sep;58(Suppl 2):97S-103S
pubmed: 28864620
Recent Results Cancer Res. 2013;194:467-78
pubmed: 22918776
J Nucl Med. 2002 May;43(5):610-6
pubmed: 11994522
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Ann Nucl Med. 2017 Jun;31(5):347-356
pubmed: 28316066
J Nucl Med. 2010 Mar;51(3):383-90
pubmed: 20150247
Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):9-15
pubmed: 12483404
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1207-1214
pubmed: 28246882
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717
pubmed: 30267116
Semin Nucl Med. 2002 Apr;32(2):110-22
pubmed: 11965606
Radiother Oncol. 2012 Jan;102(1):45-50
pubmed: 21885142
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1955-63
pubmed: 26112388
Am J Roentgenol Radium Ther Nucl Med. 1962 Jan;87:171-82
pubmed: 13867399